InspireMD, Inc. (NYSEMKT:NSPR) Files An 8-K Other Events
Item 8.01
| Other Events. |
On March 9, 2017, InspireMD, Inc. (the Company) announced the
pricing of a best efforts public offering of up to 1,171,875
shares of Series C Convertible Preferred Stock, five-year
warrants to purchase up to 4,687,500 shares of common stock and
six-month warrants to purchase up to 4,687,500 shares of common
stock. The Company expects to receive gross proceeds of up to
$7.5 million from this offering, before deducting placement agent
fees and estimated offering expenses, assuming completion of the
maximum offering. The offering is expected to close on or about
March 14, 2017, subject to customary closing conditions.
A copy of the press release announcing these events is attached
as Exhibit 99.1 to this Current Report on Form 8-K and is hereby
incorporated by reference herein.
| Item 9.01 | Financial Statements and Exhibits. |
(d)Exhibits
| Exhibit Number | Description | |
| 99.1 |
Press release dated March 9, 2017, announcing the pricing of a public offering of up to $7.5 million |
About InspireMD, Inc. (NYSEMKT:NSPR)
InspireMD, Inc. is a medical device company. The Company is focusing on the development and commercialization of its MicroNet stent platform technology for the treatment of vascular and coronary disease. Its MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. Its CGuard carotid embolic prevention system (CGuard EPS) combines its MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. Its MGuard Prime Embolic Protection System (MGuard Prime EPS) is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). It markets and sells MGuard Prime EPS, a bare-metal cobalt-chromium based stent, for the treatment of coronary disease in the European Union. It is also developing a neurovascular flow diverter (NGuard), which is an endovascular device. InspireMD, Inc. (NYSEMKT:NSPR) Recent Trading Information
InspireMD, Inc. (NYSEMKT:NSPR) closed its last trading session down -0.68 at 1.29 with 340,337 shares trading hands.